Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts

Journal of the National Cancer Institute

Volumn 85, Issue 7, 1993, Pages 546-553

  Tsai, S c Jane ^a   Gransbacher, Bernd ^b   Tait, Larry ^a   Miller, Fred R ^a   Heppner, Gloria H ^a  

^a Meyer L Prentis Comprehensive Cancer Center of Metropolitan Detroit ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; BREAST TUMOR; CARCINOGENICITY; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; IMMUNOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMAL; BASE SEQUENCE; CELLS, CULTURED; FEASIBILITY STUDIES; FEMALE; FIBROBLASTS; GENETIC VECTORS; IMMUNOTHERAPY; INTERLEUKIN-2; MAMMAE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RETROVIRIDAE; SUPPORT, NON-U.S. GOV'T; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0027466382     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.7.546     Document Type: Article

References (45)

1. Miller AD: Human gene therapy comes of age. Nature 357:455-460, 1992.
2. Gutierrez AA, Lemoine NR, Sikora K: Gene therapy for cancer. Lancet 339:715-721, 1992.
3. Gansbacher B, Zier K, Daniels B, et al: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224, 1990.
4. Colombo MP, Modesti A, Parmiani G, et al: Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52:4853-4857, 1992.
5. Gastl G, Finstad CL, Guarini A, et al: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52:6229-6236, 1992.
6. Heppner GH: Tumor heterogeneity. Cancer Res 44:2259-2265, 1984.
7. Dexter DL, Calabresi P: Intraneoplastic diversity. Biochim Biophys Acta 695:97-112, 1982.
8. Poste G, Greig R: On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion Metastasis 2:137-176, 1982.
9. Miller BE, Miller FR, Wilburn D, et al: Dominance of a tumor subpopulation line in mixed heterogeneous mouse mammary tumors. Cancer Res 48:5747-5753, 1988.
10. Miller BE, Miller FR, Wilburn D, et al: Analysis of tumour cell composition of tumours composed of paired mixtures of mouse mammary tumour cell lines. Br J Cancer 56:561-569, 1987.
11. Aslakson CJ, Moler FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399-1405, 1992.
12. Dexter DL, Kowalski HM, Blazar BA, et al: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38:3174-3181, 1978.
13. Bell E, Ivarsson B, Merrill C: Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sri U S A 76:1274-1278, 1979.
14. Louis D, Verma IM: An alternative approach to somatic cell gene therapy. Proc Nad Acad Sci U S A 85:3150-3154, 1988.
15. Tada H, Shiho O, Kuroshima K, et al: An improved colorimetric assay for interleukin 2. J Immunol Methods 93:157-165, 1986.
16. Miller FR, McInerney D: Epithelial component of host-tumor interactions in the orthotopic site preference of a mouse mammary tumor. Cancer Res 48:3698-3701, 1988.
17. Tseng SCG, Jarvtnen M, Nelson WG, et al: Correlation of specific keratins with different types of epithelial differentiation: Monoclonal antibody studies. Cell 30:361-372, 1982.
18. Lazarides E: Intermediate filaments as mechanical integrators of cellular space. Nature 283:249-256, 1980.
19. Old U, Boyse EA, Clarke DA, et al: Antigenic properties of chemically induced tumors. Ann N Y Acad Sri 101:80-106, 1962.
20. Palmer TD, Rosman GJ, Osborne WR, et al: Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Nad Acad Sri U S A 88:1330-1334, 1991.
21. Scharfmann R, Axelrod JH, Verma IM: Long-term in vivo expression of retrovirus-mediated gene transfer in mouse’ fibroblast implants. Proc Nad Acad Sri U S A 88:4626-4630, 1991.
22. Tsai SCI, Gaffney EV: Moduladon of cell proliferation by human recombinant interleukin-1 and immune interferon. JNC1 79:77-81, 1987.
23. Tsai SJ, Miller FR, Wei WZ, et al: Tumor necrosis factor modulates growth of normal and neoplasuc murine mammary cells. Proc Am Assoc Cancer Res 33:269, 1992.
24. MrKi S, Iwano M, Miki Y, et al: Interleukin-6 (IL-6) functions as an autocrine growth factor in renal cell carcinomas. FEBS Lett 250:607-610, 1989.
25. Mulé JJ, Custer MC, Travis WD, et al: Cellular mechanisms of the andtumor aedvity of recombinant IL-6 in mice. J Immunol 148:2622-2629, 1992.
26. Reif AE: Some key problems for success of classical immunotherapy. In Immunity to Cancer (Reif AE, Mitchell MS, eds). New York: Academic Press, 1985, pp 3-16.
27. Bursuker I, Petty BA, Neddermann KM, et al: Immunomoduladon in an apparently non-immunogenic murine tumor. Int J Cancer 9:414-420, 1991.
28. Mertelsmann R, Welte K: Restorative immunotherapy with interleukin 2. In Immunity to Cancer (Reif AE, Mitchell MS, eds). New York: Academic Press, 1985, pp 485-498.
29. Yoshino I, Yano T, Murata M, et al: Tumor-reacdve T cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 52:775-781, 1992.
30. Tada T, Ohzeki S, Utsumi K, et al: Transforming growth factor-fi-tnduced inhibiuon of T cell function. Suscepdbility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing stale. J Immunol 146:1077-1082, 1991.
31. Tsai SJ, Wei WZ, Pauley RJ, et al: Comparison of growth factor production among mouse mammary lines with different biological potential. Proc Am Assoc Cancer Res 31:248, 1990.
32. Miller FR: Intratumor immunologic heterogeneity. Cancer Metastasis Rev 1:319-334, 1982.
33. Miller FR, Heppner GH: Antigenic heterogeneity and metastasis. In Immune Responses To Metastasis (Herberman R, Wiltrout R Govelik E, eds). Boca Raton, FL: CRC Press, 1987, pp 23-33.
34. Palmer TD, Thompson AR, Miller AD: Production of human factor IX in animals by genetically modified skin fibroblasts: Potential therapy for hemophilia B. Blood 73:438-445, 1989.
35. Liu Y, Janeway CA Jr.: Cells that present both specific ligand and constimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci U S A 89:3845-3849, 1992.
36. + thymocytes. Nature 330:170-173, 1987.
37. Jenkins MK, Taylor PS, Norton SD, et al: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 147:2461-2466, 1991.
38. Reiser H, Freeman GJ, Razi-Wolf Z, et al: Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sri USA 89:271-275, 1992.
39. Williams TM, Moolten DM, Makni H, et al: CD28-stimulated IL-2 gene expression in Jurkat T cells occurs in part transcriptionally and is cyclosporine-A sensitive. J Immunol 148:2609-2616, 1992.
40. Mescher MF: Surface contact requirements for activation of cytotoxic T lymphocytes. J Immunol 149:2402-2405, 1992.
41. Camps JL, Chang S-M, Hsu TC, et al: Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA 87:75-79, 1990.
42. Stewart THM, Tsai SCJ: A review of the possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin Exp Metastasis. In press.
43. Miller FR, McEachern D, Miller BE: Growth regulation of mouse mammary tumor cells in collagen gel cultures by diffusible factors produced by normal mammary gland epithelium and stromal fibroblasts. Cancer Res 49:6091-6097, 1989.
44. Singh S, Ross SR, Acena M, et al: Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 175:139-146, 1992.
45. Sobol RE, Fakhrai H, Gjerset R, et al: Cytokine gene therapy: Active tumor immunotherapy with transduced fibroblasts. Proc Am Assoc Cancer Res 33:495, 1992.